drugset / Trial / NCT00823225

Urokinase Therapy in Patients With Diabetic Foot Syndrome

NCT00823225

Phase 3 Terminated 5 enrolled medac GmbH
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the additional therapy with low dose urokinase is more effective than only a conventional standard therapy concerning ulcer-healing, rate of major amputation and survival.

Timeline

Start
2008-06
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Urokinase Protein / enzyme biologic 500000 iu
Subject Urokinase Protein / enzyme biologic 1e+06 iu